AbbVie's Humira, Merck's Keytruda and more: Top 10 drugs of 2024 by Eric Sagonowsky Thursday, June 7, 2018 Blockbusters Humira and Keytruda will lead 2024 sales, according to an EvaluatePharma report, joined by new Sanofi launch Dupixent.
Celgene dealmaker Golumbeski makes a quiet exit by Eric Sagonowsky Monday, May 21, 2018 Celgene's business development chief George Golumbeski left the company in April as Celgene struggles to recover from months of setbacks.
FDA tries to shame drugmakers over tactics that delay generics by Eric Palmer Friday, May 18, 2018 FDA Commissioner Scott Gottlieb has turned to an unusual tactic to tackle drug pricing through generics competition.
Celgene, AbbVie extract pricing gains as Gilead, J&J meds net less by Eric Sagonowsky Tuesday, April 3, 2018 Higher net prices for Humira and Revlimid fueled growth in the fourth quarter for AbbVie and Celgene, respectively, a report found.
Celgene COO Smith exits suddenly in wake of MS miss by Arlene Weintraub Tuesday, April 3, 2018 The departure of Celgene COO Scott Smith wasn't entirely surprising, given recent setbacks, including a delayed FDA decision on the company's MS candidate ozanimod.
Relax, Celgene investors. The situation isn't all that bad: analyst by Carly Helfand Thursday, March 29, 2018 Celgene’s stock has taken a beating thanks to a string of bad news. But the situation isn’t as dire as its share price suggests, one analyst insists.
On the heels of its Juno buy, Celgene posts double-digit growth by Eric Sagonowsky Thursday, January 25, 2018 Despite struggles in 2017, Celgene turned in 16% annual sales growth, buoyed by key drugs Revlimid, Pomalyst and Otezla.
Celgene expects growth as it puts setbacks behind it by Eric Sagonowsky Monday, January 8, 2018 SAN FRANCISCO—Looking to recover from a tough year, Celgene rolled out its 2018 guidance at the J.P. Morgan Healthcare conference in San Francisco.
Celgene's latest Revlimid fail raises bigger questions: analyst by Tracy Staton Friday, December 22, 2017 On a quest to make Revlimid a go-to lymphoma med, Celgene pitted a Revlimid-Rituxan combo against standard of care. It failed.
Celgene wipes $1B to $2B off its 2020 guidance by Eric Sagonowsky Thursday, October 26, 2017 Celgene on Thursday reported third-quarter financial results that further spooked investors.
